Table 1.
The effects of small molecules on signaling pathways related to HCC
Pathway | Small molecule | Target | Cell line | Animal model | Result | Ref. | |
---|---|---|---|---|---|---|---|
TGF-B | Galunisertib (LY2157299) |
Phase II/III in HCC |
Receptor | SK-HEP1, HepG2, Hep3B, Huh7 | – |
Decrease proliferation, increase apoptosis In combination with Sorafenib, the anti-cancer effects was increased in concentration dependent manner |
[42] |
PD98059 | – | ERK | HepG2 | 7 × 105 HepG2 intraperitoneal into nude mice |
Inhibit proliferation, migration, invasion, and tumor growth – |
[45] | |
Wnt | IC-2 | – | TCF/β-catenin | Huh7, HepG2, HLF | Huh7 spheres to flank of NOD/SCID mice |
Decrease the CSC subpopulation – |
[63] |
CGP049090/ PKF115-854 |
-/ PMID: 23,626,717 |
TCF/β-catenin | Huh7, HepG2, | 1 × 107 HepG2 subcutaneously to Nude mice |
Induce apoptosis, cell cycle arrest, inhibit tumor growth – |
[191] | |
Hh | Cyclopamine |
Phase III |
SMO receptor | Huh7, PLC, SM-7721, | 5 × 106 Mistheton Lectin-1 into the left liver of mice |
Induce apoptosis, inhibit tumor growth -/- |
[74, 192] |
GANT61 | – | Gli | Huh7, Hep3B, HepG2 | 1 × 107 Huh7 cells to flank of SCID mice |
Induce the autophagy and apoptosis, Inhibit the HCC tumor growth Similar to Sorafenib, increase the apoptosis |
[71] | |
GDC-0449 |
Phase II |
SMO receptor | Huh7, MHCC97 | 5 × 106 MHCC97subcutaneously to syngeneic rat |
Decrease the angiogenesis Combined with Sorafenib can modulate the VEGF expression |
[69] | |
Notch | PF-4014 |
Phase II https://clinicaltrials.gov/ct2/show/NCT02299635?cond=PF-03084014&draw=2&rank=1 |
γ-secretase | MHCC97, Huh7 | 1 × 106 MHCC97-H or 4 × 105 CSC subcutaneously to nude or SCID mice then tumor cubes were then implanted into nude mice liver lobes |
Inhibited the proliferation of HCC and CSC self-renewal, decrease the tumor volume, and suppress the liver tumor metastasis PF-03084014 in combination with cisplatin or doxorubicin increase the anti-cancer effects |
[80] |
GSI |
Phase II |
γ-secretase | Bel7404, HepG2 | – |
Decrease the HCC proliferation and colony formation – |
[81] | |
EGF | Brivanib |
Phase II |
Tyrosine kinase receptor | Hep3B, HepG2, Huh7 | DEN to rat |
HCC apoptosis, cell cycle arrest, inhibit the liver tumor growth – |
[193] |
U0126 | – | Erk | HCCLM3, HepG2 | – |
Decrease proliferation – |
[87] | |
BEZ-235/ SHBM1009 | PhaseII, https://clinicaltrials.gov/ct2/show/NCT01288092/- | PI3K | |||||
HGF | PHA665752 | – | c-met | MHCC97l Huh7, Hep3B | 3 × 105 MHCC97 subcutaneously to nude mice |
Inhibit proliferation, tumor growth, and CSC, increase apoptosis – |
[93] |
AMG 337 | Phase I/II, https://clinicaltrials.gov/ct2/show/NCT02096666 | c-met | MHCC97, HCCLM3, Hep3B, SNU, JHH5 | human primary HCC tumor tissues Subcutaneously injecting nude mice |
Decrease proliferation, tumor growth – |
[95] | |
Indo5 | – | c-met |
HepG2, A549, SMMC-7721 MHCC97H |
2 × 106 HepG2, 4 × 106 MHCC 97H, 4 × 106 MHCC 97 L, 2 × 106 A549 cells, or 5 × 106 SMMC-7721 subcutaneously to flank of SCID mouse MHCC97H subcutaneously to flank of SCID mouse then insert tumor into liver |
Inhibit proliferation, migration, and metastasis Similar or better result in animal model recovery compared with Sorafenib In contrast to Sorafenib without body weight lost |
[94] | |
VEGF | Bufalin | – | VEGFR/EGFR | SMMC-7721, PLC | 5 × 106 SMMC-7721 subcutaneously to flank of nude mice |
Inhibit angiogenesis, HCC migration, and proliferation The anti-cancer effects of Bufalin improved in combination with Sorafenib |
[194] |
Stat3 | Jaki | – | Jak | Huh7, Hep3B, HepG2 | – |
Increase apoptosis Sensitize the HCC to anti-cancer effects of Sorafenib |
[112] |
C188-9 | – | Stat3 | PLC, HepG2, Huh7 | HepPten- mice Non-alcoholic steatohepatitis (NASH) |
Decrease the survival of HCC, reduce the HCC proliferation, decrease the secretion of inflammatory factors – |
[113] | |
S3i-201 | – | Stat3 | Huh7, Hep3B, HepG2 | – |
Induce HCC apoptosis and enhance the Sorafenib effects Increase the anti-cancer effects of Sorafenib |
[112] | |
UA | – | Stat3 | Huh7, HepG2, SM-7721, Hep3B | 1 × 107 HepG2 subcutaneously into flank of nude mice |
Increase the HCC apoptosis, inhibit the tumor growth – |
[114] | |
2-Ethoxystypandrone | Stat3 | HepG2 | – |
Induce apoptosis and cell cycle arrest, inhibit the CSC self-renewal – |
[115] | ||
YAP/TAZ | verteporfin | – | YAP/TEAD | Huh7, MLP29 | IP injection of DENA to Rats |
Decrease the colony formation, survival, and tumor colony – |
[125] |
HIF | PT2385 | Phase I, https://clinicaltrials.gov/ct2/show/NCT02293980 | HIF-2a | HepG2, Sk-hep1 | of 1 × 106 SK-Hep1 intrahepatic injections to nude mice |
Increase the efficiency of Sorafenib treatment, decrease invasion and survival Increase the anti-cancer effects of Sorafenib |
[136] |
Cell cycle | Dinaciclib | Phase I https://clinicaltrials.gov/ct2/show/NCT01711528?cond=Dinaciclib&draw=2&rank=2 | Cdk1,2,5,9 | Hep3B, HLE | 1 × 106 Huh7 cells or 2 × 106 PLC BALB/c subcutaneously to nude mice |
Decrease the colony formation, survival, induce cell cycle arrest, decrease the tumor size Similar results with Sorafenib |
[143] |
Ribociclib | – | CylinD/cdk4,6 | Huh7, HepG2, Hep3B, PLC | – |
Decrease cell proliferation Synergist effects with Sorafenib and anti-cancer effects on Sorafenib resistance-HCC lines |
[144] | |
Apoptosis | Tumstatin | – | Akt/mTOR | Huh7, Hep3B | 5 × 106 Hep3B cells subcutaneously to armpit of nude mice |
Induce apoptosis, cell cycle arrest, autophagy, decrease the tumor growth, increase the apoptotic proteins – |
[171] |
Brivanib | – |
FGF, VEGF, P53 |
Huh7, HepG2, Hep3B, | Rat with DENA |
Induce cell cycle arrest and apoptosis – |
[82] | |
Nutlin | – | MDM | Huh7, SM-7721, | – |
Inhibit proliferation and survival – |
[161] | |
Rubone | – | miR-34a, Bcl2, cyclinD | HepG2, HuH7, Hep3B | 5 × 106 HepG2 to dorsal flanks of nude mice |
Activate the miR34 and inhibit the TGF-B pathway and tumor growth Stronger than Sorafenib |
[162] | |
Autophagy | Verteporfin | lysosom | HepG2, HuH7 | 2 × 106 HepG2 to dorsal flanks of nude mice |
Induce autophagy Increase the anti-cancer effects with Sorafenib |
[173] | |
NVP-BGT226 | – | mTOR | Hep3B, HepG2, SNU475, Mahlavu | – |
Induce autophagy More sensitive to Sorafenib |
[174] | |
Mitoxantrone | – | mTOR | HepG2, HuH7 | – |
Induce autophagy – |
[170] | |
ROS | Propyl gallate | – | ROS formation | HepJ5, Hep3B, Mahlava | 200 HepJ5 or Hep3B injected to yolk of zebrafish embryos |
Decrease proliferation, increase apoptosis and autophagy – |
[186] |
Auranofin | – | TXNRD | Hep3B | – |
Increase apoptosis – |
[184] |